Signals, Powered By EquityPandit
Zydus Cadila has received final approval to market Doxycycline Hyclate Capsules USP, 50 mg and 100 mg, from the USFDA.
It is a tetracycline antibiotic which is used for treating variety of bacterial infections, including those that cause acne. This medication is also used for prophylaxis of malaria. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.
Further, the group has above 195 approvals and has till now filed above 330 ANDAs, since the commencement of the filing process in FY2003-04.
